LB P4
Alternative Names: LB-P4Latest Information Update: 20 Jun 2022
At a glance
- Originator LISCure Biosciences
- Class Antidementias; Antiparkinsonians; Bacteria
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Alzheimer's disease; Parkinson's disease
Most Recent Events
- 20 Jun 2022 Preclinical trials in Parkinson's disease in South Korea (unspecified route), prior to June 2022 (LISCure Biosciences pipeline, June 2022)
- 20 Jun 2022 LISCure Biosciences plans a phase I trial for Parkinson's disease and Alzheimer's disease, in 2023 (LISCure Biosciences pipeline, June 2022)
- 27 Jul 2021 Preclinical trials in Alzheimer's disease in South Korea (unspecified route), prior to July 2021 (LISCure Biosciences pipeline, July 2021)